Recent Updates — GMAB
Genmab announced positive topline results from the global Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The investigational antibody-drug conjugate met its primary endpoint of progression-free survival and key secondary endpoint of overall survival compared to investigator’s choice chemotherapy. In the intent-to-treat population, Rina-S demonstrated a 71% reduction in the risk of disease progression or death (HR 0.29) and a statistically significant improvement in overall survival (HR 0.43). The safety profile was consistent with prior data, showing no new safety signals. Genmab plans to engage with regulatory authorities worldwide regarding potential next steps for approval. Genmab is an international biotechnology company dedicated to developing innovative antibody medicines for cancer and other serious diseases.
Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the third quarter of 2026 totaled USD 4,239 million. This figure includes both intravenous and subcutaneous formulations reported by licensee Johnson & Johnson. Sales in the U.S. accounted for USD 2,528 million, while the rest of the world contributed USD 1,711 million. Genmab receives royalties on these worldwide net sales under an exclusive license agreement with J&J to develop, manufacture, and commercialize daratumumab. This disclosure provides key revenue metrics from its primary commercial partner for the quarter.
At an Extraordinary General Meeting held on October 7, 2026, Genmab A/S shareholders approved the Board of Directors' proposal regarding remuneration for 2026. The resolution included the grant of a total of 5,300 restricted stock units (RSUs) to board members in accordance with the company's Remuneration Policy. Each RSU is awarded cost-free and provides a conditional right to receive one share of Genmab A/S, valued at DKK 2,487.00 based on the closing market price on the grant date. The units are scheduled to vest three years from the grant date. Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.
Genmab A/S and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial. The study evaluated fixed-duration subcutaneous epcoritamab combined with standard-of-care R-CHOP versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index score of 2 to 5. The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, reducing the risk of disease progression or death by 51% (Hazard Ratio 0.49; p-value < 0.0001). The safety profile was generally well tolerated. Genmab and AbbVie plan to engage global regulatory authorities regarding next steps for this investigational combination therapy. Genmab is an international biotechnology company dedicated to developing innovative antibody medicines.